This is a “ what if “ scenario Since nobod
Post# of 154009
(Total Views: 676)
Posted On: 01/31/2021 7:39:33 PM
Re: Goosebumps #75427
This is a “ what if “ scenario
Since nobody really did the math assignment for the Gilead comparison. I will do a rough look right now for you.
1000 shares doubled 5 times = 32000 shares.
32000 shares x current Gilead price $65.60= $2,099,200 total value
Take that 1000 shares divide from $2,099,220= $2099.20 each Gilead share
So $2099.20 would be their stock price had they not split their stock 5 times. If we are able to steal some or most of HIV market from them and have cancer approved maybe this year and all the COVID-19 approvals world wide. Granted this is one hell of a lot of speculation of good things to come. But “what if “ we could compare ourselves with another big Pharma and In 10 years essentially with more and more indications from just Leronlimab coming through the trial pipeline. Cytodyn becoming a big Pharma compared to Gilead. It’s not that far of a stretch math wise for some of those blockbusters to get us a $1000 a share.
It may not be real yet or never all the way a real happening thing. But the potential makes it fun to imagine just how lucrative a fledgling little biotech could grow into a top 5 international Pharmaceutical...
If you want to have some fun. Sit down and run the numbers but plug your share amount in instead of using 1000 shares.
But please sit down when your doing it. It will knock your socks off...
Since nobody really did the math assignment for the Gilead comparison. I will do a rough look right now for you.
1000 shares doubled 5 times = 32000 shares.
32000 shares x current Gilead price $65.60= $2,099,200 total value
Take that 1000 shares divide from $2,099,220= $2099.20 each Gilead share
So $2099.20 would be their stock price had they not split their stock 5 times. If we are able to steal some or most of HIV market from them and have cancer approved maybe this year and all the COVID-19 approvals world wide. Granted this is one hell of a lot of speculation of good things to come. But “what if “ we could compare ourselves with another big Pharma and In 10 years essentially with more and more indications from just Leronlimab coming through the trial pipeline. Cytodyn becoming a big Pharma compared to Gilead. It’s not that far of a stretch math wise for some of those blockbusters to get us a $1000 a share.
It may not be real yet or never all the way a real happening thing. But the potential makes it fun to imagine just how lucrative a fledgling little biotech could grow into a top 5 international Pharmaceutical...
If you want to have some fun. Sit down and run the numbers but plug your share amount in instead of using 1000 shares.
But please sit down when your doing it. It will knock your socks off...
(2)
(0)